REDWOOD CITY, Calif.–(BUSINESS WIRE)–InterVene, Inc., a privately held medical device company advancing interventional care for venous disease, today announced the successful completion of 30 cases using the Recana® Thrombectomy Catheter System. The cases were performed across the company’s limited US market release and its European first-in-human study. “We’ve had the privilege of partnering with some of the most experienced and knowledgeable physicians to reach this important milestone,” sa
Other News
Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe
IRVINE, Calif.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) today announced the launch of VARIPULSE Pro in Europe following CE Mark approval, further advancing its pulsed field ablation (PFA) portfolio. This new pulse sequence marks the next evolution of the VARIPULSE Platform and is designed to improve procedural efficiencyi,ii while reinforcing its established […]
HeartFocus and Inteleos Launch First AI Cardiac POCUS Certification
Rigorous training and certification gives clinicians a validated pathway to AI-enabled cardiac POCUS proficiencyROCKVILLE, Md. and BORDEAUX, France, April 07, 2026 (GLOBE NEWSWIRE) — HeartFocus, the AI-enabled cardiac imaging software developed by data-driven medtech company DESKi, today announced a partnership with Inteleos® through its Point-of-Care Ultrasound (POCUS) Certification Academy™. Together, they are launching the HeartFocus POCUS Certification, a fast, accessible, and comprehensive training pathway designed to provide healthcare professionals with a structured pathway to AI proficiency in cardiac ultrasound and to help them confidently perform high-quality heart scans at the point of care with HeartFocus. As cardiovascular disease continues to rise, AI-powered cardiac POCUS is emerging as a cost-effective way to expand access to earlier detection. While AI adoption in healthcare has accelerated, training and trust have lagged — this collaboration closes the gap by operationalizing competency and validation for frontline users. A recent HeartFocus study revealed that 69% of Americans are comfortable with AI-enabled cardiac care, signaling that clinicians and patients are ready for AI; what has been missing is a validated, competency-based route to use it responsibly. The HeartFocus POCUS Certification was developed with this in mind, combining DESKi’s HeartFocus AI-enabled cardiac imaging solution with the POCUS Certification Academy’s rigorous assessment standards to provide a structured course with guided hands-on scanning and expert image review to validate cardiac POCUS proficiency across diverse care settings. Key elements include: Structured training and assessment: covering core cardiac ultrasound fundamentals and the use of HeartFocus, followed by a final knowledge assessment within a competency-based framework.Practical skills validation: remote evaluation of images created using HeartFocus, by experts to assess diagnostic quality and confirm consistent performance.Recognized certification: a personal credential demonstrating verified competency in cardiac POCUS using HeartFocus, enabling clinicians and institutions to demonstrate responsible AI use. “POCUS is rapidly becoming a core competency for clinicians everywhere, but education and objective skills validation must keep pace with technology,” said Jasmine Rockett, Inteleos® POCUS Certification Academy Director. “While AI adoption in healthcare has accelerated, training and trust have lagged — this collaboration closes that gap by providing a validated, competency-based route to use AI responsibly. Through this partnership with DESKi and the launch of the HeartFocus POCUS Certification, we are offering a scalable, competency-based pathway that helps clinicians gain confidence in cardiac ultrasound assisted by AI while helping health systems standardize quality and reduce variability in care.” Bertrand Moal, PhD, MD, CEO of DESKi said, “HeartFocus was created to make world-class echocardiography accessible to any trained healthcare professional at the bedside. The response since our launch has been overwhelmingly positive, but clinicians have communicated that confidence is a barrier. This certification closes that gap, giving healthcare professionals a practical way to build skills and bring high-quality cardiac imaging into everyday care.” The certification is available for healthcare institutions or medical professionals globally, and helping organizations operationalize trusted, competency-based AI use in cardiac POCUS. To learn more about The HeartFocus POCUS Certification, visit www.pocus.org/heartfocus About Inteleos Inteleos™ is a non-profit organization dedicated to ensuring equitable access to quality healthcare globally. It oversees the American Registry for Diagnostic Medical Sonography® (ARDMS®), the Alliance for Physician Certification & Advancement™ (APCA™), and the Point-of-Care Ultrasound Certification Academy™ (PCA), collectively representing 150,000+ certified medical professionals worldwide. About HeartFocusHeartFocus is an FDA-cleared, AI-powered cardiac ultrasound application designed to expand access to diagnostic-quality heart imaging at the point of care. Using real-time AI guidance and automatic image quality validation, it enables healthcare professionals – including physicians, nurses, PAs, and NPs – to capture clinical-grade cardiac ultrasound scans after just hours of training. Built on proprietary algorithms trained on millions of data points and validated through clinical studies, HeartFocus supports standard transthoracic views and integrates with existing ultrasound and DICOM/PACS workflows. Developed by DESKi, HeartFocus is driven by the belief No heart can wait™, helping clinicians identify cardiac conditions earlier across primary care, emergency, and frontline settings. Learn more at www.heartfocus.ai HeartFocus by DESKi Inquiries: Pernille Bruun-Jensen, Chief Growth Officermediarelations@deski.ai Inteleos Inquiries: Lisa Jordan, Director of Brand Strategy and Communications Lisa.jordan@inteleos.org
Endospan Receives FDA Approval for the NEXUS® Aortic Arch Stent Graft System
TEL AVIV, Israel–(BUSINESS WIRE)– #aortaEd–Endospan, a privately-held company pioneering solutions for the endovascular repair of aortic arch disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the NEXUS® Aortic Arch Stent Graft. FDA approval was supported by the one-year results of the TRIOMPHE Investigational Device Exemption (IDE) Study evaluating the NEXUS® System shown to effectively treat aortic arch disease, including chronic aortic dissections, in patients at
Route 92 Medical Announces $50 Million Growth Financing
New investor Sectoral Asset Management joins growth financing round to support acceleration of commercial growth April 7, 2026 WEST JORDAN, Utah— Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced a $50 million growth financing. New investor Sectoral Asset Management joined […]
Merakris Therapeutics Provides FDA Update and Reports Interim Findings for MTX-001 in Venous Leg Ulcers
RESEARCH TRIANGLE PARK, N.C., April 07, 2026 (GLOBE NEWSWIRE) — Merakris Therapeutics today provided an update on recent communications with the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) application for MTX-001, an investigational biologic being developed for venous leg ulcers (VLUs).
PaceMate Appoints Cardiac Electrophysiologist and NIH-Funded Researcher Benjamin A. Steinberg, MD, MHS, FACP, FACC, FHRS as Chief Medical Officer
TAMPA, Fla.–(BUSINESS WIRE)–PaceMate, a tech-enabled cardiac device monitoring platform managing care for more than 2.3 million patients at health systems nationwide, announced the appointment of Dr. Benjamin A. Steinberg as Chief Medical Officer. A nationally recognized leader in cardiac electrophysiology, NIH-funded researcher, and author of nearly 200 peer-reviewed publications, Dr. Steinberg brings to PaceMate a rare combination of clinical depth, research rigor, and real-world expertise
Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System
Endospan’s NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissections ATLANTA, April 7, 2026 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease,…
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
Medtech industry veteran to oversee development and commercialization of PAVmed’s current and future medical device portfolio. Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University. NEW YORK, April 2, 2026 /PRNewswire/ — PAVmed Inc. (Nasdaq: PAVM) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in the […]
Egg Medical Launches EggNest™ Complete Flex: Apron-Free Protection Without Construction, Downtime or Disruption
MINNEAPOLIS, April 06, 2026 (GLOBE NEWSWIRE) — Egg Medical announces the launch of EggNest™ Complete Flex, a groundbreaking advancement in radiation protection that enables clinicians to safely work apron-free or with ultralight lead aprons—without the need for construction, structural modifications or procedural downtime. The first live case with Complete Flex will be performed by Dr. Jasvindar Singh at Barnes-Jewish Hospital on Wednesday, April 8th at 9:35 a.m. CST as a part of the ARCH 2026 meeting. “We are excited to be the first to use this novel technology in a live case and believe it is important to adopt solutions that protect everyone,” said Dr. Jasvindar Singh, Section Chief of Interventional & Structural Cardiology at Barnes-Jewish Hospital and Chairman of ARCH Consortium. “ARCH continues to innovate and remains on the cutting-edge of new technology,” said Dr. George Chrysant, Course Director of ARCH and Chief Medical Officer of Integris Cardiovascular Physicians. “I’ve used the EggNest Complete for a year and am convinced that Enhanced Radiation Protection Devices (ERPDs) should no longer be an option when the welfare of the team is at stake.” Unlike other ceiling-mounted radiation shielding systems that require extensive construction and room downtime, EggNest Complete Flex sets a new standard in radiation protection: Construction-Free: No structural changes, permitting or installation delays.Zero Downtime: Labs remain operational during installation, preserving millions in potential revenue.Cost-Saving: Eliminates renovation costs associated with other built-in shielding solutions.Clinician-Friendly: Enables apron-free workflows or the use of ultralight lead, reducing orthopedic strain and long-term injury risk. “Healthcare systems have been forced to choose between clinician safety, operational disruption, and significant capital investment,” said Gavin Philipps, Chief Commercial Officer at Egg Medical. “Now hospitals can protect their team without shutting down rooms for multiple days or spending hundreds of thousands on construction.” Health systems are under increasing pressure to improve staff retention, reduce occupational hazards and maintain procedural throughput. A recent publication in JSCAI endorsed by multiple medical societies called for broader adoption of ERPDs to address these issues¹. Adoption is accelerating; the solution is currently installed in fifteen labs nationwide, with an additional eighty labs expected to be deployed by the end of Q2. Salavitabar A, Vora A, Altschul D …ALARA+: Summit on Radiation and Orthopedic Risks in Fluoroscopic Laboratories. Journal of the Society for Cardiovascular Angiography & Interventions, 2026; 0 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/14f028e0-82c4-433b-a70a-84b9ad7c33c6 CONTACT: Susan Storm, Marketing Manager, sstorm@eggmedical.com



